# Sue Desmond-Hellmann (1958)

> Oncologa, leader biotech, ex-CEO Gates Foundation, board OpenAI e Pfizer

## Dati Essenziali

| Aspetto | Dettaglio |
|---------|-----------|
| **Nascita** | 1958, Napa, California |
| **Famiglia** | Una di sette figli; padre farmacista, madre insegnante |
| **Nazionalita'** | USA |
| **Residenza** | San Francisco Bay Area |

---

## Formazione

| Periodo | Istituzione | Dettaglio |
|---------|-------------|-----------|
| **1975** | Bishop Manogue High School | Reno, Nevada |
| **1978** | [University of Nevada, Reno](../university/university-nevada-reno.md) | BS Pre-Medicine |
| **1982** | [University of Nevada, Reno](../university/university-nevada-reno.md) | MD |
| **-** | [UCSF](../university/ucsf.md) | Residency (Chief Resident), Board certified Internal Medicine & Medical Oncology |
| **-** | [UC Berkeley](../university/uc-berkeley.md) | MPH |

---

## Carriera e Ruoli

### Timeline Professionale

| Periodo | Ruolo | Organizzazione |
|---------|-------|----------------|
| **1982-** | Intern, Chief Resident | [UCSF](../university/ucsf.md) |
| **1989-1991** | Visiting Faculty | Uganda Cancer Institute |
| **1991-1995** | Associate Director Clinical Cancer Research | Bristol-Myers Squibb |
| **1995-2009** | Clinical Scientist â†’ President Product Development | [Genentech](../company/genentech.md) |
| **2009-2014** | Chancellor | [UCSF](../university/ucsf.md) |
| **2014-2020** | CEO | [Gates Foundation](../foundation/gates-foundation.md) |
| **2017-oggi** | Senior Advisor | BDT Capital |
| **2020-oggi** | Board of Directors | [Pfizer](../company/pfizer.md) |
| **2024-oggi** | Board of Directors | [OpenAI](../company/openai.md) |

### Uganda Cancer Institute (1989-1991)

Ha trascorso due anni in Uganda con il marito (medico infettivologo) studiando HIV/AIDS e sarcoma di Kaposi. Progetto finanziato dalla Rockefeller Foundation.

### Bristol-Myers Squibb (1991-1995)

Associate Director of Clinical Cancer Research. Project team leader per **Taxol**, chemioterapico innovativo.

### Genentech (1995-2009)

14 anni di carriera nella biotech di San Francisco:

| Periodo | Ruolo |
|---------|-------|
| **1995** | Clinical Scientist |
| **1996** | Chief Medical Officer |
| **1999** | EVP Development and Product Operations |
| **2004-2009** | President Product Development |

**Achievements chiave:**
- Prima donna nell'executive committee di Genentech
- Ha guidato lo sviluppo di **Herceptin** e **Avastin**, primi farmaci gene-targeted per il cancro

### UCSF Chancellor (2009-2014)

Nona Chancellor di UCSF, prima donna e prima persona non proveniente dall'accademia a ricoprire il ruolo.

| Aspetto | Dettaglio |
|---------|-----------|
| **Precision Medicine** | Ha promosso il nuovo campo, portandolo nell'agenda nazionale |
| **NIH Advisory Committee** | Membro per National Center for Advancing Translational Science |

### Gates Foundation CEO (2014-2020)

| Aspetto | Dettaglio |
|---------|-----------|
| **Prima** | Primo CEO medico, prima persona non ex-Microsoft e non amica dei Gates |
| **Focus** | Global health, polio eradication, malaria, HIV/AIDS |
| **Uscita** | Diventata Senior Advisor e Board Member Gates Medical Research Institute |

---

## Rete di Connessioni

### Mappa delle Appartenenze

```
                  SUE DESMOND-HELLMANN
                          |
    +----------+----------+----------+----------+
    |          |          |          |          |
    v          v          v          v          v
   UNR     Genentech     UCSF      Gates     OpenAI
 (MD 82)  (1995-09)   (2009-14)  (2014-20)  (2024-)
  Alumni   President  Chancellor    CEO      Board
```

### Board Positions (2025)

| Organizzazione | Dal |
|----------------|-----|
| [Pfizer](../company/pfizer.md) | 2020 |
| [OpenAI](../company/openai.md) | 2024 |
| National Resilience | - |
| Stand Up To Cancer | - |

### Network Professionale

| Nome | Connessione |
|------|-------------|
| [Bill Gates](bill-gates.md) | Gates Foundation CEO |
| [Bret Taylor](bret-taylor.md) | OpenAI board colleague |
| [Sam Altman](sam-altman.md) | OpenAI board |

---

## Potere Esercitato

### Biotech Innovation

| Aspetto | Dettaglio |
|---------|-----------|
| **Herceptin** | Ha guidato sviluppo del primo farmaco gene-targeted per cancro al seno |
| **Avastin** | Terapia anti-angiogenesi per tumori |
| **Precision Medicine** | Champion del campo, ha influenzato policy nazionale |

### Global Health

| Aspetto | Dettaglio |
|---------|-----------|
| **Gates Foundation** | Ha guidato la piu' grande fondazione filantropica del mondo |
| **Focus areas** | Polio, malaria, HIV/AIDS, maternal health |
| **Budget** | ~$5B/anno in grants durante il suo mandato |

### AI & Healthcare Governance

| Aspetto | Dettaglio |
|---------|-----------|
| **OpenAI board** | Porta expertise medica nella governance AI |
| **Pfizer board** | Oversight su pharma + AI integration |

---

## Riconoscimenti

| Anno | Riconoscimento |
|------|----------------|
| **2009** | California Hall of Fame |
| **-** | Forbes "100 Most Powerful Women" |
| **-** | TIME "100 Most Influential People" (multiple years) |

---

## Connessioni PowerLink

### Organizzazioni

| Entita' | Connessione |
|---------|-------------|
| [University of Nevada, Reno](../university/university-nevada-reno.md) | Alumni BS 1978, MD 1982 |
| [UC Berkeley](../university/uc-berkeley.md) | Alumni MPH |
| [UCSF](../university/ucsf.md) | Chancellor (2009-2014) |
| [Genentech](../company/genentech.md) | President Product Development (1995-2009) |
| [Gates Foundation](../foundation/gates-foundation.md) | CEO (2014-2020) |
| [Pfizer](../company/pfizer.md) | Board (2020-) |
| [OpenAI](../company/openai.md) | Board (2024-) |

### Persone

| Persona | Relazione |
|---------|-----------|
| [Bill Gates](bill-gates.md) | Gates Foundation |
| [Bret Taylor](bret-taylor.md) | OpenAI board |
| [Sam Altman](sam-altman.md) | OpenAI board |

---

## Timeline

| Anno | Evento |
|------|--------|
| **1958** | Nasce a Napa, California |
| **1978** | BS Pre-Medicine, University of Nevada, Reno |
| **1982** | MD, University of Nevada, Reno; inizia residency UCSF |
| **1989** | Parte per Uganda Cancer Institute (2 anni) |
| **1991** | Entra in Bristol-Myers Squibb; team leader Taxol |
| **1995** | Entra in Genentech come clinical scientist |
| **1996** | Chief Medical Officer Genentech |
| **2004** | President Product Development Genentech |
| **2009** | Chancellor UCSF (prima donna) |
| **2014** | CEO Gates Foundation |
| **2020** | Lascia Gates Foundation; entra nel board Pfizer |
| **2024** | Entra nel board OpenAI |

---

## Fonti

### Biografie
- [Wikipedia - Sue Desmond-Hellmann](https://en.wikipedia.org/wiki/Sue_Desmond-Hellmann)
- [UCSF History - Susan Desmond-Hellmann](https://history.library.ucsf.edu/desmond_hellmann.html)
- [California Museum - Hall of Fame](https://californiamuseum.org/inductee/susan-desmond-hellmann-m-d-m-p-h/)

### Media
- [STAT News - Q&A with Gates Foundation CEO](https://www.statnews.com/2020/01/21/qa-gates-foundation-ceo-sue-desmond-hellmann/)
- [GV - Sue Desmond-Hellmann](https://www.gv.com/team/sue-desmond-hellmann)

### Istituzionali
- [Pfizer Board](https://www.pfizer.com/people/leadership/board_of_directors/susan_desmond-hellmann-md-mph)
- [UCSF Profile](https://globalhealthsciences.ucsf.edu/ighs-25th-anniversary/meet-our-speakers/sue-desmond-hellmann-md-mph/)

---

*Ultimo aggiornamento: Gennaio 2026*
